Please download the dossier by clicking on the dossier button x
×

TREATMENT OF CANCER USING CHIMERIC CD3 RECEPTOR PROTEINS

  • US 20180230193A1
  • Filed: 08/05/2016
  • Published: 08/16/2018
  • Est. Priority Date: 08/07/2015
  • Status: Active Grant
First Claim
Patent Images

1. A chimeric membrane protein comprising a CD3 gamma, delta, or epsilon domain and an intracellular co-stimulatory domain, wherein said CD3 domain comprises an extracellular domain derived from the extracellular domain of CD3 gamma, delta, or epsilon and said intracellular co-stimulatory domain is not derived from CD3 gamma, delta, or epsilon.

View all claims
  • 3 Assignments
Timeline View
Assignment View
    ×
    ×